Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more
Dongsung Pharm (002210) - Total Liabilities
Latest total liabilities as of June 2025: ₩107.40 Billion KRW
Based on the latest financial reports, Dongsung Pharm (002210) has total liabilities worth ₩107.40 Billion KRW as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dongsung Pharm - Total Liabilities Trend (2008–2024)
This chart illustrates how Dongsung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dongsung Pharm Competitors by Total Liabilities
The table below lists competitors of Dongsung Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Airthings ASA
PINK:ARTGF
|
USA | $13.66 Million |
|
J.S.P. Property Public Company Limited
BK:JSP
|
Thailand | ฿419.85 Million |
|
NextCell Pharma AB
ST:NXTCL
|
Sweden | Skr10.34 Million |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
USA | $29.26 Million |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
Thailand | ฿1.33 Billion |
|
Cadence Opportunities Fund Ltd
AU:CDO
|
Australia | AU$13.30 Million |
|
Murray & Roberts Holdings Limited
PINK:MURSF
|
USA | $647.00 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Dongsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dongsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dongsung Pharm (2008–2024)
The table below shows the annual total liabilities of Dongsung Pharm from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩96.73 Billion | +28.69% |
| 2023-12-31 | ₩75.17 Billion | +15.84% |
| 2022-12-31 | ₩64.89 Billion | +11.61% |
| 2021-12-31 | ₩58.14 Billion | -17.84% |
| 2020-12-31 | ₩70.77 Billion | +14.83% |
| 2019-12-31 | ₩61.63 Billion | -25.49% |
| 2018-12-31 | ₩82.71 Billion | +38.05% |
| 2017-12-31 | ₩59.91 Billion | -14.12% |
| 2016-12-31 | ₩69.77 Billion | +8.37% |
| 2011-12-31 | ₩64.38 Billion | -6.30% |
| 2010-12-31 | ₩68.71 Billion | +14.63% |
| 2009-12-31 | ₩59.94 Billion | +5.62% |
| 2008-12-31 | ₩56.75 Billion | -- |